# Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF

> **NCT06655480** · PHASE2 · RECRUITING · sponsor: **National Medical Research Center for Cardiology, Ministry of Health of Russian Federation** · enrollment: 50 (estimated)

## Conditions studied

- HFpEF
- LVDD
- Myocardial Fibrosis

## Interventions

- **DRUG:** [ARNI + SGLTi + AMR]
- **DRUG:** [SGLTi + previously taken RAAS blocker]

## Key facts

- **NCT ID:** NCT06655480
- **Lead sponsor:** National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-18
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06655480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06655480, "Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06655480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*